Status:
UNKNOWN
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Angelman Syndrome
Smith-Magenis Syndrome
Eligibility:
All Genders
3-50 years
Brief Summary
A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi sy...
Detailed Description
A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi Sy...
Eligibility Criteria
Inclusion
- Patients with one of the following rare diseases associated with : Angelman syndrome, Smith-Magenis syndrome, X Fragile syndrome, rare diseases of the cerebellum, rare epilepsies, PW-like syndromes or other rare diseases with eating disorders
- Patients aged minimum 3 years and maximum 50 years.
- Patients with overweight (or obesity) and/or hyperphagic behavior.
Exclusion
- Administrative problems: impossibility of giving parents or legal guardians informed information ; no coverage by a Social Security scheme.
Key Trial Info
Start Date :
June 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04768803
Start Date
June 10 2021
End Date
December 15 2023
Last Update
August 24 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre N°1 : 40 Centre de Référence PRADORT Pr Tauber - Toulouse Centre N°2 : 22 Centre de Référence PRADORT Pr Poitou Bernert - Paris La Pitié Salpetrière Centre N°3 : 15 Centre de Référence DI de causes rares Dr Heron - Paris La Pitié Salpêtrière Centr
Paris, France
2
Tauber
Toulouse, France